Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone
- Conditions
- schizophrenic patients (F20.0, F20.1, F20.2, F20.3, F20.5, F20.6, F20.8, F20.9) and healthy controls
- Registration Number
- EUCTR2007-004857-27-DE
- Lead Sponsor
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. written informed consent
2. schizophrenic patients (according to ICD-10) and healthy controls
3. aged 18 to 55 (patients and healthy subjects)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
substance abuse, any kind of neurological or psychiatric disorder despite schizophrenia, somatic disorders of clinical relevance, allergy against serdolect or risperdal, metal in the body (e.g. implants), cardiac pacemaker, pregnancy, lactation, agoraphobia
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Aim of this study is to investigate neural activity associated with anticipation and receipt of a financial gain or loss, respectively, and to examine the influence of Sertindol (Serdolect ©) and Risperidon (Risperdal ©) on these processes.<br>;Secondary Objective: ;Primary end point(s): Neuronal activity (Bold-signal; PET) in schizophrenic patients before and after treatment with atypic neuroleptica (serdolect; risperdal) <br>
- Secondary Outcome Measures
Name Time Method